Comparative Pharmacology
Head-to-head clinical analysis: PENICILLIN G SODIUM versus PENICILLIN 2.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PENICILLIN G SODIUM versus PENICILLIN 2.
PENICILLIN G SODIUM vs PENICILLIN-2
Head-to-head clinical comparison of therapeutic indices and safety profiles.
Penicillin G inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidase activity, and activating autolytic enzymes.
Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidase activity, and activating autolytic enzymes.
Streptococcal infections (including Group A, B, C, G, H, K, L, M)Pneumococcal infections (Streptococcus pneumoniae)Meningococcal infections (Neisseria meningitidis)Syphilis (Treponema pallidum)ActinomycosisClostridial infections (including tetanus and gas gangrene)Listeriosis (Listeria monocytogenes)Rat-bite fever (Streptobacillus moniliformis)Fusospirochetal infections (Vincent's angina)Anthrax (Bacillus anthracis)Diphtheria (Corynebacterium diphtheriae - as adjunct)Endocarditis prophylaxis (for certain dental and invasive procedures)
Streptococcal infectionsPneumococcal infectionsMeningococcal infectionsSyphilisLyme diseaseAnthraxActinomycosisProphylaxis for rheumatic fever
2-4 million units intravenously every 4 hours for moderate to severe infections; up to 24 million units/day for severe infections (e.g., meningitis, endocarditis).
250 mg orally every 6 hours or 500 mg orally every 8 hours for mild to moderate infections; intravenous dosing: 1-2 million units every 4-6 hours.
None Documented
None Documented
30-60 minutes in normal renal function; prolonged to 7-10 hours in anuria.
30-60 minutes; prolonged in renal impairment (up to 10 hours in anuria)
Primarily eliminated unchanged by renal tubular secretion; minor hepatic metabolism to penicilloic acid (inactive).
Primarily eliminated unchanged by renal tubular secretion; minor hepatic metabolism to penicilloic acid.
Primarily renal (60-90% unchanged) via glomerular filtration and tubular secretion; minor biliary/fecal (<10%).
Renal: 60-80% unchanged; biliary/fecal: minor (10-20%)
60-80% bound to serum albumin.
50-65% bound, primarily to albumin
0.3-0.5 L/kg; approximates extracellular fluid volume, limited CNS penetration unless inflamed meninges.
0.3-0.5 L/kg; low Vd indicates limited tissue penetration
IM: 60-80%; oral: <30% (not clinically used).
Oral: 60-70% (decreased with food); IM: 70-85%
CrCl 10-50 mL/min: administer every 6-8 hours; CrCl <10 mL/min: administer every 8-12 hours. For high-dose therapy (e.g., >10 million units/day), reduce dose by 50% when CrCl <10 mL/min.
For CrCl 10-50 mL/min: administer every 8-12 hours; for CrCl <10 mL/min: administer every 12-18 hours; hemodialysis: give after dialysis.
No significant hepatic metabolism; dose adjustment not required for Child-Pugh Class A, B, or C. Monitor for electrolyte disturbances with high doses.
No specific Child-Pugh based dose adjustment; use with caution in severe hepatic impairment.
Neonates: 50,000-100,000 units/kg/day divided every 12 hours (postnatal age ≤7 days, weight ≤2 kg) to every 8 hours (older neonates). Infants/children: 100,000-250,000 units/kg/day divided every 4-6 hours; maximum 24 million units/day. For meningitis: 300,000-400,000 units/kg/day divided every 4-6 hours.
For children >1 month: 25-50 mg/kg/day orally divided every 6-8 hours; severe infections: 100-250 mg/kg/day IV divided every 4-6 hours; maximum 12 g/day.
Initiate at lowest recommended adult dose (2 million units IV every 4 hours) with careful renal function monitoring. Adjust dose based on CrCl as per renal adjustment. Monitor for neurotoxicity (seizures) at high doses or with decreased renal function.
No specific dose adjustment except for renal function; monitor renal function and adjust dose accordingly.
No FDA black box warning.
No FDA black box warning.
["Severe hypersensitivity reactions (anaphylaxis) can occur; cross-sensitivity with cephalosporins.","Use with caution in renal impairment (dose adjustment required).","Prolonged use may lead to superinfection.","Neurologic adverse effects (seizures) with high doses, especially in renal failure.","Jarisch-Herxheimer reaction when treating syphilis."]
["Hypersensitivity reactions including anaphylaxis","Severe cutaneous adverse reactions (e.g., Stevens-Johnson syndrome)","Clostridioides difficile-associated diarrhea","Renal impairment requiring dose adjustment","Neurologic toxicity with high doses (seizures)"]
["Hypersensitivity to penicillin or any component of the formulation.","Do not use in patients with immediate-type hypersensitivity reactions (urticaria, anaphylaxis) to cephalosporins."]
["Hypersensitivity to penicillins","History of severe immediate hypersensitivity reaction to beta-lactam antibiotics"]
Data Pending Review
Data Pending Review
No significant food interactions. However, avoid alcohol as it may reduce drug effectiveness and slow recovery.
No significant food interactions. Can be taken with or without food.
Penicillin G is classified as FDA Pregnancy Category B. Animal studies have not demonstrated fetal risk, and no adequate controlled studies in pregnant women exist. Across all trimesters, no known teratogenic effects have been reported; risk is considered low.
Penicillin is generally considered low risk; no significant teratogenic effects have been consistently reported in first trimester. Animal studies show no fetal harm. Use is considered safe across all trimesters when indicated.
Penicillin G is excreted in breast milk in low concentrations (M/P ratio approximately 0.1-0.2). It is generally considered compatible with breastfeeding, but potential for neonatal sensitization or diarrhea exists. Use with caution.
Penicillin is excreted into breast milk in low concentrations (M/P ratio approximately 0.2). It is compatible with breastfeeding; no adverse effects on nursing infants reported. Caution in infants with history of penicillin allergy.
No dose adjustment is typically required during pregnancy. However, increased plasma volume and renal clearance may lower serum concentrations; in severe infections, higher doses or more frequent administration may be considered, though evidence is limited.
Increased renal clearance in pregnancy may reduce serum concentrations; higher doses may be required for severe infections, but standard dosing is generally adequate. No specific dose adjustment is uniformly recommended; monitor clinical response.
Category A/B
Category C
Administer IV only; IM can cause severe pain and sterile abscess. Contraindicated in patients with immediate hypersensitivity to penicillins. Perform skin testing prior to use in suspected allergy. Monitor renal function as clearance is primarily renal. For neurosyphilis, use high doses (18–24 million units/day). Use within 24 hours after reconstitution due to rapid loss of potency.
Penicillin-2 (benzathine penicillin G) is indicated for syphilis and group A streptococcal infections. Intramuscular injection only; avoid intravenous administration. Monitor for Jarisch-Herxheimer reaction. Dose adjustment in renal impairment is not typically required due to slow release.
Complete the full course of antibiotics even if you feel better.Report any rash, hives, or difficulty breathing immediately.This medication is given intravenously, not by mouth.May cause diarrhea; contact your doctor if persistent or bloody.Inform your doctor if you are pregnant, breastfeeding, or have kidney disease.
Complete the full course as prescribed, even if symptoms improve.Report any rash, difficulty breathing, or swelling immediately.Avoid alcohol during treatment to minimize side effects.Do not stop or change the dose without consulting your doctor.Inform all healthcare providers about this therapy.